Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis has entered into a structured collaboration with the laboratory of Tobias Kollmann at the University of British Columbia (UBC) to develop live attenuated Listeria vaccines for the treatment of infectious disease and for new dosage forms of Listeria vaccines.
Subscribe to our email newsletter
As per the terms of this collaboration, Kollmann is expected to use Advaxis proprietary Listeria vaccine vectors for the development of novel infectious disease applications, and employ a post-doctoral fellow who will be dedicated to the creation and assessment of novel infectious disease vaccines and new delivery forms of live attenuated Listeria vaccines.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer
Kollmann is an immunologist and neonatal vaccinologist who has published on the use of Listeria vaccines as potential therapeutic agents for the treatment of childhood diseases.